The Incidence and Timing of Treatment-Requiring Retinopathy of Prematurity in Nanopremature and Micropremature Infants in the United States : A National Multicenter Retrospective Cohort Study
Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved..
PARTICIPANTS: This article includes 7293 infants (14 586 eyes) screened for ROP across 5 centers in the United States (Austin Retina Associates, Austin, TX; Bascom Palmer Eye Institute, Miami, FL; Beaumont Eye Institute, Royal Oak, MI; Massachusetts Eye and Ear, Boston, MA; and Stanford Byers Eye Institute, Stanford, CA).
PURPOSE: To analyze the incidence and timing of treatment requiring retinopathy of prematurity (ROP) in extremely small premature infants. We hypothesize that the smaller the infant by gestational age and birthweight, the higher their likelihood of requiring treatment for ROP.
DESIGN: Premature infants screened for Retinopathy of Prematurity from 2002-2022 were divided into cohorts based on the following criteria based on gestational age (GA) and birth weight (BW). "Micropremature infants" are infants born between 24-26 weeks GA and between 600-799 g BW. "Nanopremature infants" are born ≤ 24 weeks GA and ≤ 600 g BW.
METHODS: Retrospective chart review.
MAIN OUTCOME MEASURES: The incidence and timing of treatment-requiring ROP.
RESULTS: We found that infants defined as nanopremature had a ∼63% chance of requiring treatment at an average postmenstrual age (PMA) of 36.6 weeks, whereas those defined as micropremature had a 30% chance of requiring treatment at an average PMA of 36.3 weeks. This significantly contrasts with the risk of all screened babies for ROP where the risk of requiring treatment was 8.5%.
CONCLUSION: Micropremature and nanopremature infants are significantly more likely to require treatment for ROP. With demographic data matched to all 5 major US regions spanning the last decade, these results have the potential to inform neonatologists, pediatricians, and ophthalmologists of an important shift in the landscape of prematurity in the United States.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Ophthalmology. Retina - 8(2024), 3 vom: 15. März, Seite 279-287 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarboro, Shannon D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 08.03.2024 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oret.2023.10.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363312315 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363312315 | ||
| 003 | DE-627 | ||
| 005 | 20240308232109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oret.2023.10.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM363312315 | ||
| 035 | |a (NLM)37838276 | ||
| 035 | |a (PII)S2468-6530(23)00495-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarboro, Shannon D |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Incidence and Timing of Treatment-Requiring Retinopathy of Prematurity in Nanopremature and Micropremature Infants in the United States |b A National Multicenter Retrospective Cohort Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PARTICIPANTS: This article includes 7293 infants (14 586 eyes) screened for ROP across 5 centers in the United States (Austin Retina Associates, Austin, TX; Bascom Palmer Eye Institute, Miami, FL; Beaumont Eye Institute, Royal Oak, MI; Massachusetts Eye and Ear, Boston, MA; and Stanford Byers Eye Institute, Stanford, CA) | ||
| 520 | |a PURPOSE: To analyze the incidence and timing of treatment requiring retinopathy of prematurity (ROP) in extremely small premature infants. We hypothesize that the smaller the infant by gestational age and birthweight, the higher their likelihood of requiring treatment for ROP | ||
| 520 | |a DESIGN: Premature infants screened for Retinopathy of Prematurity from 2002-2022 were divided into cohorts based on the following criteria based on gestational age (GA) and birth weight (BW). "Micropremature infants" are infants born between 24-26 weeks GA and between 600-799 g BW. "Nanopremature infants" are born ≤ 24 weeks GA and ≤ 600 g BW | ||
| 520 | |a METHODS: Retrospective chart review | ||
| 520 | |a MAIN OUTCOME MEASURES: The incidence and timing of treatment-requiring ROP | ||
| 520 | |a RESULTS: We found that infants defined as nanopremature had a ∼63% chance of requiring treatment at an average postmenstrual age (PMA) of 36.6 weeks, whereas those defined as micropremature had a 30% chance of requiring treatment at an average PMA of 36.3 weeks. This significantly contrasts with the risk of all screened babies for ROP where the risk of requiring treatment was 8.5% | ||
| 520 | |a CONCLUSION: Micropremature and nanopremature infants are significantly more likely to require treatment for ROP. With demographic data matched to all 5 major US regions spanning the last decade, these results have the potential to inform neonatologists, pediatricians, and ophthalmologists of an important shift in the landscape of prematurity in the United States | ||
| 520 | |a FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Micropremature | |
| 650 | 4 | |a Nanopremature | |
| 650 | 4 | |a Neonatology | |
| 650 | 4 | |a Premature | |
| 650 | 4 | |a Retinopathy of prematurity | |
| 700 | 1 | |a Harper, Clio Armitage |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Karsaliya, Gopal |e verfasserin |4 aut | |
| 700 | 1 | |a Ghoraba, Hashem |e verfasserin |4 aut | |
| 700 | 1 | |a Moshfeghi, Darius M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Khersan, Hasenin |e verfasserin |4 aut | |
| 700 | 1 | |a Robles-Holmes, Hailey Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Kenneth C |e verfasserin |4 aut | |
| 700 | 1 | |a Berrocal, Audina M |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyek, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Nimesh A |e verfasserin |4 aut | |
| 700 | 1 | |a Sbrocca, Rocco |e verfasserin |4 aut | |
| 700 | 1 | |a Capone, Antonio |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Drenser, Kimberly A |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Edward H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmology. Retina |d 2017 |g 8(2024), 3 vom: 15. März, Seite 279-287 |w (DE-627)NLM271223650 |x 2468-6530 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:3 |g day:15 |g month:03 |g pages:279-287 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oret.2023.10.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 3 |b 15 |c 03 |h 279-287 | ||